Industry News
Biotechnology Industry News
Just months after laying off a…
Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive treatment, Seres Therapeutics is pausing that investment and sending more employees to the exits.
BridgeBio is hoping that…
BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.
For all of the groundbreaking…
For all of the groundbreaking advancements in cancer treatment over the last decades, the first step for tackling almost all solid tumors is still surgery. If the cancer comes back, medicines like immunotherapies can then
Massachusetts’ largest life…
Massachusetts’ largest life science employer has put more than 630,000 square feet of office space on the sublease market as part of efforts to consolidate the Japanese company’s U.S. corporate hub at a new Cambridge
After the FDA’s surprise refusal…
After the FDA's surprise refusal to take up a review of Moderna's next-gen flu vaccine, the public disagreement between U.S. regulators and the mRNA specialist took another turn Wednesday.
Whisper it, but we may finally be…
Whisper it, but we may finally be seeing the IPO window reopening in 2026.
Madrigal Pharmaceuticals is…
Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra.
A phase 2 asthma study of Upstream…
A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation rate, the readout fell
The FDA specifically took issue…
The FDA specifically took issue with the trial's control arm, which incorporated a "licensed standard-dose seasonal influenza vaccine," per Moderna's press release.
In an effort to bolster Europe’s…
In an effort to bolster Europe’s biotech venture capital ecosystem, investment firms, research institutions and other stakeholders have launched the European Life Sciences Coalition.
Nektar Therapeutics is basking in…
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and itchiness of patients’ eczema after 52
Evommune has aced its first major…
Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading.
AstraZeneca is taking its oral…
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the drug actually performed.
AstraZeneca executives have told…
AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates.
Kailera Therapeutics and its China…
Kailera Therapeutics and its China partner Hengrui have released top-line results from a phase 2 trial of their oral version of ribupatide that indicate it has a “potentially game-changing clinical profile,” according to Kailera’s chief medical
OrsoBio’s experimental oral drug…
OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions.
After facing a delayed decision…
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by the FDA.
Eli Lilly has become the latest…
Eli Lilly has become the latest Big Pharma to buy itself into a corner of the in vivo CAR-T space via the acquisition of Orna for up to $2.4 billion.
Roche has shared the numbers…
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis, linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to Ocrevus.
Eli Lilly is heading back to its…
Eli Lilly is heading back to its regular Chinese collaborator Innovent with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders.